Managing Capillary Leak Syndrome and Adverse Events in BPDCN Treatment
October 19th 2023Expert perspectives on the sequencing of treatment options for blastic plasmacytoid dendritic cell neoplasm, considering patient age, response to tagraxofusp, venetoclax-based therapies, clinical trials, and future possibilities for targeted agents.
Watch
Understanding How BPDCN Manifests in Clinical Practice
October 19th 2023A key opinion leader identifies the clinical manifestations and diagnostic markers of blastic plasmacytoid dendritic cell neoplasm, shedding light on its presentation and diagnostic significance in real-world medical settings.
Watch
Patient Case: An 87-Year-Old Man With Blastic Plasmacytoid Dendritic Cell Neoplasm
October 19th 2023Expert James Foran, MD, discusses the challenging case of an 87-year-old patient diagnosed with blastic plasmacytoid dendritic cell neoplasm (BPDCN), its diagnosis, and treatment options, highlighting the unique considerations for elderly individuals.
Watch
Moving Beyond JAK Inhibition for the Treatment of Myelofibrosis
October 18th 2023Aaron T. Gerds, MD, MS, discusses available treatment options for patients with myelofibrosis and some of the agents that are currently under development, inching toward regulatory approval in the field of myelofibrosis.
Watch
Bright Future of Lung Cancer Research: Targeted Therapies and Immunotherapy Advancements
October 16th 2023Expert Sandip Patel, MD, looks toward the promising future of lung cancer research, including targeted therapies, novel immunotherapy approaches, and the importance of biomarkers in guiding treatment decisions.
Watch
Tailoring Lung Cancer Treatment: Balancing Immunotherapy, Chemotherapy, and Targeted Therapies
October 16th 2023Insight into key patient characteristics and considerations in determining the optimal approach for treating metastatic non-small cell lung cancer, including the role of chemotherapy, immunotherapy, and targeted therapy.
Watch
Efficacy of Perioperative Pembrolizumab/Chemotherapy in Early NSCLC
October 9th 2023Heather Wakelee, MD, discusses the efficacy findings from the phase 3 KEYNOTE-671 clinical trial evaluating the addition of pembrolizumab to neoadjuvant platinum-based chemotherapy followed by resection and adjuvant pembrolizumab alone for patients with early-stage non–small cell lung cancer.
Watch